Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The fact that they aren’t buying shares speaks a thousand words.
Up again today. 40’s could be here soon.
Is anyone still here?
Hopefully with the end of tax loss selling the stock makes a recovery. More positive trial results could be the trigger.
That’s pretty much what happened at a high level. Although there wasn’t any bankruptcy filing. The company didn’t go bankrupt, it defaulted on a loan and had to forfeit the assets that were held as collateral.
The big question is whether this was just a series of bad decisions or if it was orchestrated by certain people who profited from it.
Waiting for what? What do you think is going to happen?
She must not have had a kung fu grip on her seat.
I think it reverses in the new year. Tax loss selling is at its peak.
H.C. Wainwright reiterated Buy rating, set price target of $4.
https://www.smarteranalyst.com/brief/h-c-wainwright-keeps-a-buy-rating-on-protalix-biotherapeutics-plx/
Cara Therapeutics Assumed At Buy By Janney, Price Target At $27/Share
12/20/2018 (MT Newswires) -- Cara Therapeutics (CARA) received an investment rating of buy Thursday from Janney Montgomery Scott as analyst Esther Hong assumed coverage of the biopharmaceutical company's stock with a price target of $27 per share, more than double the stock's Wednesday closing price of $13.36.
In a note to clients, Janney highlighted Cara's lead program, IV-Korsuva, which is in two ongoing phase 3 trials for moderate-to-severe pruritus in patients with chronic kidney disease on hemodialysis (CKD-aP). Janney noted IV-Korsuva has the potential to be the first approved treatment for CKD-aP.
The firm noted Cara is also evaluating oral Korsuva in pre-dialysis CKD-aP patients, a larger population for which there is no Food & Drug Administration-approved therapy. It added that expansion opportunities include chronic liver disease-associated pruritus, atopic dermatitis and psoriasis.
In turn, Janney said, "2019 will be a transformative year with [phase] 3 data kicking off Korsuva for potential use across multiple indications starting with CKD-aP."
The firm said its price target on the stock of $27 each is based on discounted cash flows.
At Janney, the stock was previously covered by Ken Trbovich, who also had a buy rating and a $27 price target on the stock as of early November.
That’s a good question and they need to answer it. Stop paying themselves huge salaries and start buying shares.
Nope. Looks like we’re headed for the 20’s. This is insane.
thanks for the detailed perspective on the latest news. How the market cap is just $50M and trending down for a company with so much potential defies logic. Where's the bottom?
Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease
https://globenewswire.com/news-release/2018/12/17/1667809/0/en/Protalix-BioTherapeutics-Announces-the-Completion-of-Enrollment-in-the-Phase-III-BRIDGE-Clinical-Trial-of-pegunigalsidase-alfa-for-the-Treatment-of-Fabry-Disease.html
Well on that basis it’s all good for anyone looking to acquire shares. Unfortunately for shareholders the demand for shares is falling off a cliff as the price sinks further and further sub penny.
That's been the story for the past year. It's looking more and more like a dead end.
That must be some company update to generate this buying
I remember sunspotter. If my memory is accurate he was really vicious towards barnhill and another guy terry hallinan always defended barnhill even after it became obvious barnhill was screwing over investors for personal gain.
I always thought the technology would overcome the drama and investors would win. I couldn’t have been more wrong.
Not bitter. Just sick of big beef attacking anybody who posts a question or makes a comment.
Sure. Some big fish spent 2 cents. Wow. Must be a sign.
Yeah sure. Which explains why the stock has fallen back down under 1 penny. If you’re so convinced take your own advice and buy.
Wtf is your problem?
I agree that it’s more likely this is positive for shareholders. I don’t understand though, if it’s a technical secret, why they wouldn’t have already patented that for protection from competitors.
hopefully not as that would destroy the stock price. These tests move incredibly slowly, even with a big research partner like MD Anderson.
Devil dog. Do you agree the only reason anyone is here is for day trading?
Take it however you like but presuming my intent is foolish.
Good point. I wouldn’t put anything past them when it comes to making money.
Looks like it’s just riding on the coattails of related companies that are up big today.
Ok. So the business is day trading. Good to know.
What good are these filings if they don’t follow through on anything? Other than a reverse split which they seem to have cancelled what plans do they have to create an actual business? Or is the business to keep submitting filings to generate stock sales?
Over 1 year and no deal no news no nothing.
It’s all speculation. No agreement or settlement reached as far as I know. If there is a settlement that pays out to shareholders please do share
So one more month until we find out
At least his wife lost her re-election this month. It’s the only satisfaction this stock will ever provide
We just need to be patient. Sometimes these huge deals can take decades or even centuries to be finalized.
Lol we’ve learned over and over what this stock can do. It’s great at sucking in buyers only to crash back down within 24 hours.
The volume is still pitiful for a penny stock.
I have more shares than all 3 days of volume combined. I’d love to see something positive happen so if you know of anything please do share.
Are your prices missing a decimal place? This hasn’t seen 9 cents for years.
We need new buyers. Existing shareholders are likely not buying until something positive happens
Just another day at MBRX. Big pop on news followed by crash back to where it started.
No way. I’ve got more than enough of this crap.